Mentions
Extended reach
Total likes
Video views
AI synopsis
The collective discussions showcase enthusiasm for the promising role of sGFAP as a biomarker in multiple sclerosis, with comments highlighting its clinical potential and referencing specific data like the Swiss MS cohort and findings in JAMA Neurology. The tone varies from supportive to cautious, with some posts emphasizing the importance of further studies, indicating a balanced perception of impact.
Most discussions recognize the research's findings supporting sGFAP as a valuable biomarker, with some posts questioning aspects like follow-up duration, indicating overall cautious agreement.
The discussion demonstrates high interest, especially with references to new data, clinical implications, and connections to ongoing research in multiple sclerosis.
Posts include summaries of study results and contextual comments, reflecting a moderate level of deep engagement, though some are more commentary or sharing links.
Participants perceive the findings as potentially significant for disease management and future research, although some suggest the need for further validation before full clinical implementation.
Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of relapse activity in patients with #multiplesclerosis. https://t.co/maflOM94rS
Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of relapse activity in patients with #multiplesclerosis. https://t.co/IqF1193wIW
Congratulations @JensKuhle and team!
Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of relapse activity in patients with #multiplesclerosis. https://t.co/qt7m8BWIIe
“Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis” by Stephanie Meier et al. JAMA Neurology https://t.co/ZPFLKkhzak
Using data from 355 #SwissMScohort participants, @UniBasel researchers @JensKuhle, @CagolAlessandr0, @ThINk_Basel, @BarakMuhamed et al. identified a blood biomarker for progression risk in individuals with #multiplesclerosis. Out now in @JAMANeuro ⬇️ https://t.co/ZjLrEocBCm
Experts gather at ECTRIMS 2024 in Copenhagen to discuss personalized MS treatments, genetic risk factors, gender differences, and the benefits of early high-efficacy therapies. The event includes keynotes, research…
This video covers personalized MS treatments, genetic risk factors, gender differences, and the benefits of early highly effective therapies, highlighting recent research and developments presented at ECTRIMS 2024.
Serum Glial Fibrillary Acidic Protein & Multiple Sclerosis:
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis https://t.co/ooWbFtglEL #FacultyDevelopment #AcademicMedicine @FSUFaculty @CMUforsuccess @ucdhFD @MayoFacDev @HarvardMacy
@GavinGiovannoni Couldn’t these findings just be due to shorter follow-up in comparison to studies that deemed sGFAP as a good predictor of disability accumulation (like the following: https://t.co/CcvvXQGpFr)?
RT @JAMANeuro: Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of re…
RT @JAMANeuro: Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of re…
RT @JAMANeuro: Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of re…
RT @JAMANeuro: Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of re…
RT @JAMANeuro: Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of re…
RT @JAMANeuro: Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of re…
RT @JAMANeuro: Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of re…
RT @JAMANeuro: Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of re…
RT @JAMANeuro: Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of re…
Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of relapse activity in patients with #multiplesclerosis. https://t.co/maflOM94rS
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis | Demyelinating Disorders | JAMA Neurology | JAMA Network https://t.co/ON3KR2xz18
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain as Biomarkers in Multiple Sclerosis - JAMA Neurology Jour. via BrainSights for iOS https://t.co/bGXYmtuyMO
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain as Biomarkers in Multiple Sclerosis - JAMA Neurology Jour. via BrainSights for iOS https://t.co/bGXYmtv6Cm
Researchers at University of Basel have presented a biomarker for Disease Progression in Multiple Sclerosis. “Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.” https://t.co/3mg8lkI6fh
Original research: Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis https://t.co/otPqOxBkSQ Share if you like this article, follow Lumosa for more topics like this.
RT @SAOscience: Using data from 355 #SwissMScohort participants, @UniBasel researchers @JensKuhle, @CagolAlessandr0, @ThINk_Basel, @BarakMu…
Using data from 355 #SwissMScohort participants, @UniBasel researchers @JensKuhle, @CagolAlessandr0, @ThINk_Basel, @BarakMuhamed et al. identified a blood biomarker for progression risk in individuals with #multiplesclerosis. Out now in @JAMANeuro ⬇️ https://t.co/ZjLrEocBCm
RT @AutoimmuneList: Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in…
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis https://t.co/uTn0KaRTgQ https://t.co/5kE9apmK2v
“Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis” by Stephanie Meier et al. JAMA Neurology https://t.co/ZPFLKkhzak
Results suggest that serum glial fibrillary acidic protein (#sGFAP) is more strongly associated than #sNfL concentrations w/ disease progression in #MS, a finding with clinical implications for patient management & drug development. https://t.co/lyWzrmVLyd
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis #MS https://t.co/JjgedTGJGa
RT @DepBiomedicine: Congratulations @JensKuhle and team!
Serum Glial Fibrillary Acidic Protein Compared with Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis https://t.co/hoj5iNQwbn Both MS & AD have reported better biomarkers than NfL this week.
Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of relapse activity in patients with #multiplesclerosis. https://t.co/qt7m8BWIIe
RT @DepBiomedicine: Congratulations @JensKuhle and team!
Congratulations @JensKuhle and team!
RT @JAMANeuro: Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of re…
RT @JAMANeuro: Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of re…
RT @JAMANeuro: Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of re…
RT @JAMANeuro: Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of re…
Study suggests that serum glial fibrillary acidic protein is a prognostic biomarker for future progression independent of relapse activity in patients with #multiplesclerosis. https://t.co/IqF1193wIW